1

EFPIA EHR Integration WorkshopTopic: The Innovative Medicines Initiative

Brussels 10-03-2007

Marc Peeters Ir.Leopoldstraat 182300 TurnhoutBelgium

marc_dvf_Peeters@hotmail.com

2

What is IMI (1)Preparatory PhaseFrom ETP to JTI

Active PhaseIMI Joint Undertaking

20-12Councilapproval

04-02Publication

03-031st BoardMeeting

< 1st May1st Callpublished

• From European Technology Platform (ETP) to Joint Technology Initiative (JTI)– ETP: Create Strategic Research Agenda (SRA)

+ Initiate pilot project (InnoMed)– JTI: Create Statutes and Regulations (Structure, R+R, procedures,

processes)– Prepare hand-over: 1st IMI call / call topics documents

-EC DG RTD: Irene Norstedt-EFPIA: RDG & Ian Ragan-Stakeholder workshops

-IMI Governance Board-IMI Executive Office & Scientific Committee-IMI Member States Group & Stakeholder Forum

IMI JUautonomous

10-10IMI JTIapproval

15-09-06SRAapproved

3

What is IMI (2)

• IMI is a legal entity, a Commission Body, that will call for-, review-, approve-, fund- and oversee Research Projects implementing the IMI Research Agenda.

• It results from new and innovative approaches to Community R&D introduced with FP7 (Research Council, Joint Technology Initiatives) and as such is part of FP7 and funded by FP7 budget. JTIs are based on industry led R&D topics.

• It is a EU JTI embodied in a joint undertaking between the European Commission and the Pharmaceutical Industry represented by EFPIA.

• Is funded by the European Commission (cash, 1Billion Euro, public sector and SMEs) and the BioPharmaceutical Industry (in kind, 1Billion Euro). This covers the operations of the Executive Office (4% max) and the IMI Research Projects.

Preparatory PhaseFrom ETP to JTI

Active PhaseIMI Joint Undertaking

20-12Councilapproval

04-02Publication

03-031st BoardMeeting

< 1st May1st Callpublished

-EC DG RTD: Irene Norstedt-EFPIA: RDG & Ian Ragan-Stakeholder workshops

-IMI Governance Board-IMI Executive Office & Scientific Committee-IMI Member States Group (MSG) & Stakeholder Forum

IMI JUautonomous

10-10IMI JTIapproval

15-09-06SRAapproved

4

The drivers for action

• The need to enhance European’s competitiveness– Academic – industrial platform for bio-medical research– Network of SMEs with expertise in various niche areas– Capabilities development

• The potential for increased cooperation between stakeholders– The convergence of disciplines creates the necessity for multidisciplinary

research– The scale of the landslide change is such that a collaborative effort is required

• Wealth of novel opportunities from genomics– New undestanding leads to a continuous development of new subdisciplines– Biomolecular findings become tools for the further exploration of biomolecular

mechanisms with an acceleration of new findings and potential industrial application as a consequence

• Timelines and cost of drug development– Attrition rates and their associated costs become an unacceptable burden. – New science based Pre-dictive tools understood by scientists and by

regulators.

5

EFPIA Research Directors Group (RDG)

....Others

In line with the ETP concept of industry led R&D the Biopharma industry tookresponsibility for the creation of the Strategic Research Agenda (SRA) under the direction of the EFPIA RDG. Multiple workshops with representatives from allthe stakeholders (Academia, University hospitals, Patient organisations, SMEs,Regulators, non-Pharma- and Pharma industry, EU Commission) shaped the SRA.

6

Efficacy

Safety

Predictive pharmacology

Predictive toxicology

Identification of biomarkers

Validation of biomarkers

Benefit/Risk assessment

with regulatoryauthorities

Patient recruitment

PreclinicalresearchDiscovery

developmentTranslational

medicineClinicaldevelop.

Pharmacovigilance

The Strategic Research Agenda (1)

•Is an umbrella programme that describes the kind of advanced pre-competitive research needed to broaden throughout the EU Union, the academic and industrial know-how and skills required to successfully discover and develop novel medicinal products at acceptable cost.•It is based on the the identification of the current drug development bottlenecks and suggests the drug development tools and processes that need further R&D to overcome these bottlenecks. Developing drugs is not within the scope.•It emphasizes close collaboration with the regulators to promote the acceptance and use of these new methods and tools.

7

• Identifies pre-competitive bottlenecks in the R&D process

• Proposes recommendations to address these bottlenecks

– Safety

– Efficacy (Cancer, Brain Disorders, Metabolic diseases, Infectious diseases, Inflammatory diseases)

– Knowledge Management (KM)

– Education and Training (E&T)

• Proposes a new model of Public-Private collaborations to implement these recommendations

• http://www.imi-europe.org under “Publications” tab

The Strategic Research Agenda (2)

8

• EC + EFPIA initiative• ETP >>> JTI >>> IMI Joint Undertaking• Strategic Research Agenda (SRA)

– IMI is about R&D processes including regulatoy approval– IMI is about tools and understanding of diseases, not about medicinal products– IMI is about public and private sector collaboration in pre-competive biopharmaceutical research

• Predictivice Safety and –Efficacy tools, methods and expertise– that can lead to treatments that affect disease progression and ultimately to the cure of

diseases.• 4 Pillars: Safety Efficacy KM E&T

Pre-clinical Pharmaco 5 Disease Trans IntegratedVigilance Areas lation Data

al KM Exploration Platform

• Implementation based on calls (call topics).• Project funding stems in equal amounts from EC funding and EFPIA company

contributions in kind. I.e. In a typical Research Project half of the costs are covered by in kind contributions from the participating BioPharma and other industry companies and the other half by IMI cash contributions to the participatns from SMEs and the Public sector.

Synopsis

9

• InnoMed is a FP6 project• It is a pilot demonstrating successful pre-competitive collaboration between 16

BioPharmaceutical companies, 14 Universities and 8 SMEs.• Two targets: Toxicogenomics and Alzheimer disease.

The Pilot Project ‘InnoMed’

• PredTox• www.innomed-PredTox.com• For a number of compounds from each of the participating Pharma companies

create a database of toxicity profiles.• Integrating the traditional endpoints with new data from transcriptomics,

metabonomics and proteomics.• In search of new hepatitic toxicity biomarkers.

• AddNeuroMed• www.innomed-QAddNeuroMed.com• In search of diagnostic markers

markers of progressionmarkers of response / non-response

in Alzheimer disease involving animal studies/models and clinical trials.

10

IMI Process - Pre-Call

Annual Implementation Plan

Executive Office Governance Board

Scientific CommitteeIMI Research Agenda

1st Call: Industry Scientific Priorities Survey + Preparatory team

Call Topics

RDG

MSG

Call Topic Documents

Call = Call Topic Documents Call Guidance Documents

RDGPharma Companies

Executive Office

Workshops

11

• Heading• Topic Title• Project Description (Background, Scope, Approach, Requirements, Project Plan,..)• Key Deliverables of the project (Packages, lists,...)• EFPIA participants in the project (Company, Contact person(s))• Role of EFPIA participants in the project• Indicative Duration of the project• Indicate total in kind contribution from the EFPIA companies• Indicative Expectations from the ‘Public Consortium’ (i.e. SMEs, Academia, Patient

Organisations, Regulators and non-EFPIA companies)

From 6 to 10 pages.

Call Topic ToC

12

IMI Process - Post-Call

Expression of Interest

Execu

tive O

ffice

Phase 1

Call Published

Invitation to submission

Full Project Proposal

Call = Call Topic Documents Call Guidance Documents

Phase 2

FinalizationProject AgreementGrant Agreement

Submit

Submit

13

SRA recommendations pre-Clinical Safety

1 Establish the framework for Biomarker development and validation with human relevance and regulatory utility in mind•Define datapackage needed to support acceptance of Biomarkers

2 Establish a pre-Clinical Safety data warehouse, cross species and supportive of multi-scale modelling

3 Enhance the relevance for predictive toxicology/pre-clinical, of in-vivo, in-vitro and in-silico models•determine the relevance of rodent non-genotoxic carcinogenicity: mechanistic studies to understand mechanisms of receptor-mediated carcinogenicity•develop widely applicable in-silico models of toxicity to improve the predictivity of endpoints•understand intractable toxicity….develop new animal models, cellular models, stem cells, human tissues, imaging, …..

Knowledge Management is often embedded in the Safety and Efficacy pillar recommendations. It is a matter of emphasis.

14

SRA recommendationsClinical Efficacy - Mechanism of Action based

1 •Tools for the rational selection of molecular targets•Tools for assays that demonstrate real pharmacological action and predict efficacy in human disease•Diagnostic tests capable of early detection

Need for Understanding of the disease mechanism of action

2 •In order to use methods and endpoints that most closely reflect those that could can be used in clinical trials

Need for In-silico models of disease pathology; i.e. ‘disease lifecycle models’ that directly link the rationale in pre-clinical modeling to the treatment of clinical disease. Systems Biology

3 •For improved ‘confidence in the rationale’ pre-clinical experiments must carry higher relevance in relation to the clinical experience

Need for In-vitro & in-vivo models predictive of clinical efficacy

15

SRA recommendatios Clinical Efficacy – Integrated Healthcare

7 •In order to speed-up the recruitment process and to recruit the right patient

We need Integrated patient selection networks that involve patient organisations and access first class electronic patient records (EHR) linked with Biobanks

8 •Baseline data for a number of observations derived from pooling EMEA and National agency data•EU Drug risk/benefits database compiled from patient EMR•Healtheconomics dataAre all part of Innovative Clinical trial Designs and analysis

9 Intelligent Clinical Trial Environment•EHR – CRF integration•Patient database of he future

The EFPIA EHR Integration Taskforce objectives and recommendation - Eligibility broker (CRFQ framework), EHR information broker, CRF-EHR core data sets - closely align with these expressed needs in the IMI umbrella research programme

16

SRA recommendations Pharmacovigilance

1 Optimise data resources and EU datawarehouse

2 Develop lifecycle approach to pharmacovigilance

3 Develop novel methods of risk prediction and benefit-risk assessment

4 Establish EU academic network of pharmacoepidemiology

17

SRA recommendationsKnowledge Management (KM)

Special attention for collaboration and reuse with DG INFSO ICT for Health.Open offer to present the ICT for Health programme and projects and results to IMI Governance Board and IMI staff.

1 Systematically integrate / embed KM in the Safety and Efficacy projects through the Translational KM approach

2 Develop and maintain IMI Data Exploration Platform supporting the needs of safety and efficacy researchers across projects and disease areas.

–Develop enhanced knowledge representation models and data exchange standards for complex systems–Design standards for and build an expert tool to allow the federation of local databases in a secured environment–Build a core reference database of validated experimental data–Integrate mechanistic multi-scale modeling and simulation tools that operate on top of the reference database

18

EFPIA European Commission

Brian Ager EFPIA Franco Biscontin DG RTDAndreas Busch Bayer Daniel Jacob DG RTDJackie Hunter GSK George Lalis DG ENTRCarlo Incenti Genzyme Andrzej Jan Rys DG SANCOJonathan Knowles Roche Zoran Stancic DG RTD

IMI Governance Board

IMI JU

MSG

STAKEHOLDERSFORUM

EUCOMMISSION

SCIENTIFIC COMMITTEE

EXECUTIVE OFFICE

BOARD

EFPIARDG

SA

FETY

EFF

ICA

CY

KM

E&

T

19

IMI Web site

www.imi-europe.org

Go to ‘Contact’ linkOpen ‘Contact Us’ formWrite the message, provide personal data and submit

Messages are handled by Question and Answer software at the IMI offices.IMI staff checks open questions on a daily basis and will respond asap.

IMI Contact